InDex Pharmaceuticals appoints Uli Hacksell and Jesper Wiklund to its Board of Directors

July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development.

InDex Pharmaceuticals regains European rights to Kappaproct® in ulcerative colitis

June 30, 2015 – InDex Pharmaceuticals today announced the termination of a license agreement with Almirall S.A. relating to the drug candidate Kappaproct® for the treatment of ulcerative colitis. Under the agreement, which was signed in March 2014, Almirall licensed exclusive rights to Kappaproct® for the European market. Upon termination of the agreement, InDex regains all worldwide development and commercialization rights for Kappaproct®, which is in late-stage clinical development.

Peter Zerhouni new CEO of InDex Pharmaceuticals

February 5th, 2015 – InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.

InDex Pharmaceuticals to present results from the COLLECT trial at the 10th Congress of the European Crohn’s and Colitis Organisation

February 3rd, 2015 – InDex Pharmaceuticals today announced that results from COLLECT, a clinical study of the toll-like receptor 9 (TLR9) agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis, will be subject to an oral presentation at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). The congress is to be held in Barcelona, Spain on February 18-21, 2015.

Investor contact

Peter Zerhouni
Peter Zerhouni
+46 8 122 038 50